EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy

Andrew J Doyle iD, Matthew J Stubbs iD, Tina Dutt, Will Lester iD, Will Thomas, Joost van Veen iD, Joannes Hermans iD, Tanya Cranfield, Quentin A Hill iD, Amanda Clark, Catherine Bagot iD, Steven Austin und 3 weitere

Blood · 19.01.2023 · 141 (3) · 285-294

DOI: 10.1182/blood.2022017023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood, erschienen am 19.01.2023. Verfasst von Andrew J Doyle und 14 weiteren Autor:innen. Beteiligte Einrichtung: University College London Hospitals NHS Foundation Trust, London, United Kingdom. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disease relapse is recognized as a risk in immune-mediated thrombotic thrombocytopenic purpura (iTTP) after treatment of the acute presenting episode. Identification of patients at risk of relapse and its patterns are yet to be clearly established. We reviewed patients with iTTP having had >3 years of follow-up over 10 years in the United Kingdom to identify patient characteristics for relapse, assess relapse rates and patterns, and response to anti-CD20 therapy in those with a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) relapses (ADAMTS13 activity of <20% without thrombocytopenia). We identified 443 patients demonstrating relapse rates of 40% at 5-year follow-up. At 10-year follow-up, no difference in relapse was observed irrespective of whether rituximab was used at acute presentation (P = .39). Black Caribbean ethnicity increased the risk of disease relapse in the British population. There was a distinct population of patients (6%) that relapsed early with subsequent frequent relapses occurring on average within 2 years (average time to relapse in subgroup, 1.7 years). Overall, nearly 60% of relapses described were ADAMTS13 relapses, with subsequent treatment reducing the risk of progression to clinical relapses. We demonstrate that iTTP diagnosed in the latter part of the study period had lower rates of clinical relapses (22.6% vs 11.1%, P = .0004) with the advent of regular monitoring and preemptive rituximab. In ADAMTS13 relapses, 96% responded to anti-CD20 therapy, achieving ADAMTS13 activity of >20%. Anti-CD20 therapy was demonstrated to be an effective long-term treatment regardless of relapse pattern and there was no loss of this treatment response after subsequent treatment episodes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombotic ThrombocytopenicHumansRituximabADAMTS13 ProteinRecurrenceUnited Kingdom

Substanzen

RituximabADAMTS13 Protein

Autor:innen und Institutionen

  • University College London Hospitals NHS Foundation Trust, London, United Kingdom.
  • Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom.
  • Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom.
  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
  • Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom.

ORCID-Profile: Andrew J Doyle, Matthew J Stubbs, Will Lester, Joost van Veen, Joannes Hermans, Quentin A Hill, Catherine Bagot

Zitieren

APA

Doyle, A. J., Stubbs, M. J., Dutt, T., Lester, W., Thomas, W., van Veen, J., Hermans, J., Cranfield, T., Hill, Q. A., Clark, A., Bagot, C., Austin, S., Westwood, J. P., Thomas, M., & Scully, M. (2023). Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy. Blood, 141(3), 285-294. https://doi.org/10.1182/blood.2022017023

Vancouver

Doyle AJ, Stubbs MJ, Dutt T, Lester W, Thomas W, van Veen J, et al. Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy. Blood. 2023;141(3):285-294. doi:10.1182/blood.2022017023

BibTeX
@article{Doyle2023,
  author = {Doyle, Andrew J and Stubbs, Matthew J and Dutt, Tina and Lester, Will and Thomas, Will and van Veen, Joost and Hermans, Joannes and Cranfield, Tanya and Hill, Quentin A and Clark, Amanda and Bagot, Catherine and Austin, Steven and Westwood, John-Paul and Thomas, Mari and Scully, Marie},
  title = {Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy},
  journal = {Blood},
  year = {2023},
  volume = {141},
  number = {3},
  pages = {285--294},
  doi = {10.1182/blood.2022017023}
}
Kostenlos starten →